anti-GPC3 CAR-T / CRISPR Therap, Roswell Park Comprehensive Cancer Center - LARVOL DELTA

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones (GlobeNewswire) - "CRISPR Therapeutics plans to engage with regulatory authorities to align on the path forward for CTX112 in B-cell malignancies, with an update expected in mid-2025....Clinical trials are on-going for CTX131 in both solid tumors and hematologic malignancies, with updates expected in 2025. Additionally, we are advancing an autologous, gene-edited CAR T therapy targeting glypican-3 (GPC3) for the potential treatment of solid tumors and expect to initiate a clinical trial in the first half of 2025."

New trial • P1/2 data • Regulatory • Hematological Malignancies • Solid Tumor

Development of allogeneic, potency-edited, anti-GPC3 CAR-T cells for the treatment of hepatocellular carcinoma (SITC 2023) - "Conclusions CRISPR-edited anti-GPC3 CAR-T cell therapies are a promising potential option for the treatment of HCC. We have shown that our allogeneic anti-GPC3 CAR-T cells have significant activity both in vitro and in vivo against HCC-derived cell lines, and this activity is further improved through the inclusion of potency edits."

CAR T-Cell Therapy • IO biomarker • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • TGFBR2

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) - "CRISPR Therapeutics...announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023."

Preclinical • Breast Cancer • Hepatocellular Cancer